

## KT-474

### IRAK4


oral IRAK4 degrader

Ph. II in AD and HS

via SBDD of ligands for CRBN and IRAK4, and linker

*Nat. Med.*, November 2023

KYMERA THERAPEUTICS, MA / SANOFI, NJ



## RLY-2608

### pan-mutant PI3K $\alpha$


oral allosteric pan-mutant isoform-selective PI3K $\alpha$  inhibitor

Ph. I for PIK3CA mutant cancers

from DEL screen for mutant-specific allosteric inhibitors

*Cancer Discov.*, November 2023

D.E. SHAW RESEARCH / RELAY THERAPEUTICS



## LY3522348

### hKHK-C/A


oral selective dual hKHK-C/A inhibitor

Ph. I in healthy volunteers

from fragment-based screen and SBDD

*J. Med. Chem.*, November 2023

ELI LILLY, INDIANAPOLIS, IN



## AZD9574

### PARP1


oral CNS-penetrant selective PARP1 inhibitor and trapper

Ph. I/II for advanced cancers

from binding profiling of known molecules, SBDD + PBDD

*Nat. Med.*, November 2023

ASTRAZENECA, CAMBRIDGE, UK / BOSTON, MA



## pelcitoclax

### BCL-2/xL


IV dual BCL-2/xL inhibitor prodrug

Ph. I/II for NHL

discovery undisclosed

*Clin. Cancer Res.*, November 2023

ASCENTAGE PHARMA, CN / MD



## KB-0742

### CDK9


oral selective CDK9 inhibitor

Ph. I/II for R/R solid tumors and NHL

from small-molecule microarray (SMM) screen and SBDD

*J. Med. Chem.*, November 2023

KRONOS BIO, CAMBRIDGE, MA / SAN MATEO, CA



## SF001 (AM-2-19)

### ergosterol


IV ergosterol extracting polyene antifungal

Ph. I single-ascending dose portion completed

from optimization of amphotericin B

*Nature*, November 2023

UNIVERSITY OF ILLINOIS, IL / SFUNGA, MA



## KIO-301

### HCN


IVT photoswitchable HCN channel blocker

Ph. I/II for retinitis pigmentosa and choroideremia

based on photoswitchable affinity label

*Press Release*, November 2023

UC BERKELEY, CA / KIORA THERAPEUTICS, CA



## FX-909

### PPARG


oral selective covalent PPARG inhibitor

Ph. I for solid tumors and urothelial carcinoma

from optimization of covalent inverse agonist T907

*Cancer Res.*, November 2023

FLARE THERAPEUTICS, CAMBRIDGE, MA



## AMG487

### CXCR3

oral CXCR3 antagonist

Ph. II for psoriasis and arthritis - terminated

from HTS and optimization

*Cell Discov.*, November 2023

CHEMOCENTRYX, CA / AMGEN, CA